ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review

October 2021 | 56 pages | ID: R8868225AFBEN
GlobalData

Abstracts

ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ReNeuron Group Plc (ReNeuron) is a stem cell company that develops innovative stem cell therapies targeting areas of significant unmet medical need. The company’s therapeutic candidates in clinical development are focused at treating patients left disabled by a stroke and the blindness-causing disease, retinitis pigmentosa, oncology, diabetes and neurodegenerative diseases. It utilizes exclusive stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered off-the-shelf to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron’s technology platforms include hRPC platform, CTX platform and Exosomes platform. ReNeuron is headquartered in Pencoed, Bridgend, the UK.

ReNeuron Group Plc Key Recent Developments

Aug 16,2021: Reneuron Group Posting of AR and Accounts and Notice of AGM
Aug 06,2021: ReNeuron Group:Directorate Change
Jul 14,2021: ReNeuron Group announces board change
Jul 08,2021: ReNeuron Group: Preliminary results for the year ended 31 March 2021
Jul 01,2021: ReNeuron Group : Directorate change

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

ReNeuron Group Plc - Key Facts
ReNeuron Group Plc - Key Employees
ReNeuron Group Plc - Key Employee Biographies
ReNeuron Group Plc - Major Products and Services
ReNeuron Group Plc - History
ReNeuron Group Plc - Company Statement
ReNeuron Group Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
ReNeuron Group Plc - Business Description
ReNeuron Group Plc - Corporate Strategy
ReNeuron Group Plc - SWOT Analysis
SWOT Analysis - Overview
ReNeuron Group Plc - Strengths
ReNeuron Group Plc - Weaknesses
ReNeuron Group Plc - Opportunities
ReNeuron Group Plc - Threats
ReNeuron Group Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ReNeuron Group Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 16, 2021: Reneuron Group Posting of AR and Accounts and Notice of AGM
Aug 06, 2021: ReNeuron Group:Directorate Change
Jul 14, 2021: ReNeuron Group announces board change
Jul 08, 2021: ReNeuron Group: Preliminary results for the year ended 31 March 2021
Jul 01, 2021: ReNeuron Group : Directorate change
May 20, 2021: ReNeuron Group: Appointment of Chief Scientific Officer
Mar 19, 2021: ReNeuron Group: Exosome platform update
Mar 12, 2021: ReNeuron Group Announces CFO Resignation
Nov 24, 2020: ReNeuron Group: Interim results for the six months ended 30 September 2020
Aug 12, 2020: ReNeuron Group : Changes to non-executive Board

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

ReNeuron Group Plc, Key Facts
ReNeuron Group Plc, Key Employees
ReNeuron Group Plc, Key Employee Biographies
ReNeuron Group Plc, Major Products and Services
ReNeuron Group Plc, History
ReNeuron Group Plc, Subsidiaries
ReNeuron Group Plc, Key Competitors
ReNeuron Group Plc, Ratios based on current share price
ReNeuron Group Plc, Annual Ratios
ReNeuron Group Plc, Annual Ratios (Cont...1)
ReNeuron Group Plc, Interim Ratios
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ReNeuron Group Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

ReNeuron Group Plc, Performance Chart (2017 - 2021)
ReNeuron Group Plc, Ratio Charts
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021